Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone609-662-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$36.93 million
Profitability
Miscellaneous
Employees325
OptionableOptionable
Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions
What is Amicus Therapeutics' stock symbol?
Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."
How were Amicus Therapeutics' earnings last quarter?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.00. The biopharmaceutical company earned $21.31 million during the quarter, compared to the consensus estimate of $18.92 million. Amicus Therapeutics had a negative net margin of 463.82% and a negative return on equity of 52.03%. View Amicus Therapeutics' Earnings History.
When is Amicus Therapeutics' next earnings date?
What guidance has Amicus Therapeutics issued on next quarter's earnings?
Amicus Therapeutics issued an update on its FY 2019 earnings guidance on Monday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $160-180 million, compared to the consensus revenue estimate of $173.18 million.
What price target have analysts set for FOLD?
5 Wall Street analysts have issued 12 month price objectives for Amicus Therapeutics' stock. Their forecasts range from $12.59 to $31.00. On average, they anticipate Amicus Therapeutics' stock price to reach $19.3180 in the next twelve months. This suggests a possible upside of 69.2% from the stock's current price. View Analyst Price Targets for Amicus Therapeutics.
What is the consensus analysts' recommendation for Amicus Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amicus Therapeutics.
What are Wall Street analysts saying about Amicus Therapeutics stock?
Here are some recent quotes from research analysts about Amicus Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $20 12-month PT on Amicus following initial presentations and conversations at WORLDSymposium, which we are attending. Amicus has a large presence at the conference, with the largest booth. We believe this conference will serve as an important platform, given it is one of the first major conferences following Galafold’s U.S. approval. While additional clinical data are an important part of the study, our focus remains on the patient and physician perspectives post-launch." (2/5/2019)
- 2. According to Zacks Investment Research, "2018 was great for Amicus as it received U.S. approval forits only marketed drug Galafold, expanded its pipeline to include 14 new gene therapy programs for rare metabolic diseases and also presented a positive 18-month data for its differentiated Pompe pipeline product. Amicus estimates peak sales opportunity for Galafold to be more than $500 million. The company also expects to almost double the revenues for Galafold in 2019. However, it depends heavily on Galafold sales, which remains a concern. Shares of the company have underperformed the industry in the past year. Loss estimates have remained stable ahead of the Q4 earnings release and the company came up with average negative surprise for the trailing four reported quarters." (2/4/2019)
Has Amicus Therapeutics been receiving favorable news coverage?
Press coverage about FOLD stock has been trending positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amicus Therapeutics earned a news sentiment score of 2.3 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the next few days.
Are investors shorting Amicus Therapeutics?
Amicus Therapeutics saw a drop in short interest in January. As of January 31st, there was short interest totalling 22,063,910 shares, a drop of 23.0% from the January 15th total of 28,648,935 shares. Based on an average daily volume of 2,934,535 shares, the days-to-cover ratio is presently 7.5 days. Approximately 12.0% of the company's shares are sold short. View Amicus Therapeutics' Current Options Chain.
Who are some of Amicus Therapeutics' key competitors?
Some companies that are related to Amicus Therapeutics include Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), Marina Biotech (MRNA), Perrigo (PRGO), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR) and Patheon (PTHN).
Who are Amicus Therapeutics' key executives?
Amicus Therapeutics' management team includes the folowing people:
- Mr. John F. Crowley, Chairman & CEO (Age 52)
- Mr. Bradley L. Campbell, Pres, COO & Director (Age 43)
- Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 56)
- Dr. Jay A. Barth, Chief Medical Officer (Age 55)
- Ms. Daphne E. Quimi, Chief Financial Officer (Age 53)
Who are Amicus Therapeutics' major shareholders?
Amicus Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (10.95%), BlackRock Inc. (8.73%), venBio Select Advisor LLC (5.35%), Jennison Associates LLC (5.19%), Sectoral Asset Management Inc (2.66%) and Victory Capital Management Inc. (1.66%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.
Which institutional investors are selling Amicus Therapeutics stock?
FOLD stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Orbimed Advisors LLC, Victory Capital Management Inc., Bank of America Corp DE, Asymmetry Capital Management L.P., Jennison Associates LLC, Principal Financial Group Inc. and Squarepoint Ops LLC. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Margaret G Mcglynn, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.
Which institutional investors are buying Amicus Therapeutics stock?
FOLD stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, venBio Select Advisor LLC, Assenagon Asset Management S.A., Sphera Funds Management LTD., Delek Group Ltd., Millennium Management LLC, Geode Capital Management LLC and Sectoral Asset Management Inc. Company insiders that have bought Amicus Therapeutics stock in the last two years include John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.
How do I buy shares of Amicus Therapeutics?
Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amicus Therapeutics' stock price today?
One share of FOLD stock can currently be purchased for approximately $11.42.
How big of a company is Amicus Therapeutics?
Amicus Therapeutics has a market capitalization of $2.16 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe.
What is Amicus Therapeutics' official website?
How can I contact Amicus Therapeutics?
Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]
MarketBeat Community Rating for Amicus Therapeutics (NASDAQ FOLD)
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
